Search

Displaying results 4481 - 4490 of 10000 in total
  1. Drug

    IDM-4

    go.drugbank.com/drugs/DB05438
    Experimental

    IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. … It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes.

  2. Drug

    Equine Botulinum Neurotoxin B Immune FAB2

    go.drugbank.com/drugs/DB13903
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes B in adults and pediatric patients. … Equine Botulinum Neurotoxin B Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype B.

  3. Drug

    Equine Botulinum Neurotoxin F Immune FAB2

    go.drugbank.com/drugs/DB13901
    Approved

    It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes F in adults and pediatric patients. … Equine Botulinum Neurotoxin F Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype F.

  4. Drug

    Bergamot oil

    go.drugbank.com/drugs/DB14335
    Investigational

    Bergamot oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Terbutaline

    go.drugbank.com/drugs/DB00871
    ApprovedInvestigational

    Terbutaline was first synthesized in 1966[A230333] and described in the literature in the late 1960s and early 1970s. … [A230328] It is a selective beta-2 adrenergic agonist used as a bronchodilator in asthmatic patients.[A230333,L32093,L32098] Terbutaline was granted FDA approval on 25 March 1974.[L32088]

    Categories: Adrenergic beta-2 Receptor Agonists
  6. Drug

    Haemagglutinin-strain A(H3N2)

    go.drugbank.com/drugs/DB15475
    ApprovedInvestigational

    Mixtures: Afluria Tetra Injektionssuspension in einer Fertigspritze
  7. Drug

    Haemagglutinin-strain A(H1N1)

    go.drugbank.com/drugs/DB15476
    ApprovedInvestigational

    Mixtures: Afluria Tetra Injektionssuspension in einer Fertigspritze
  8. Drug

    Bordetella pertussis toxoid antigen (glutaraldehyde inactivated)

    go.drugbank.com/drugs/DB10787
    ApprovedInvestigational

    Mixtures: ADACEL 0,5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇEREN FLAKON, 5 ADET
  9. Target

    Hypoxia-inducible factor 1

    go.drugbank.com/bio_entities/BE0010297
    TargetHumans

    Forms heterodimers with the aryl hydrocarbon receptor (AHR) to mediate the transcriptional response to xenobiotics by binding xenobiotic response elements (XREs) or dioxin response elements (DREs) in target

    Polypeptides: Aryl hydrocarbon receptor nuclear translocatorSynonyms: Dioxin receptor, nuclear translocator
  10. Drug

    ANA971

    go.drugbank.com/drugs/DB05127
    Experimental

    ANA971, an orally administered prodrug of isatoribine. Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection. … ANA971 resulted in higher levels of isatoribine in the blood than were present after oral administration of isatoribine itself.